This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Juul Labs Faces Lawsuits Due to the Wrong Demographic Using Their Product
by Nimah Quadri
The e-cigarette maker valued at $15 billion is now facing concerns from every corner due to their controversial product.
Altria (MO) Q2 Earnings: Can Smokeless Products Offset Woes?
by Zacks Equity Research
Altria's (MO) Q2 results are likely to gain from rising reduced-risk tobacco products demand. However, soft cigarette volumes are a concern.
Zacks Industry Outlook Highlights: Philip Morris International, Altria Group, British American Tobacco, Imperial Tobacco Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris International, Altria Group, British American Tobacco, Imperial Tobacco Group and Turning Point Brands
Philip Morris (PM) Beats on Q2 Earnings & Sales, Lowers View
by Zacks Equity Research
Philip Morris' (PM) second-quarter 2018 results improve year-on-year on account of strong performance of heated tobacco products.
Philip Morris (PM) Tops Q2 Earnings & Revenues, Stock Loses
by Zacks Equity Research
Phillip Morris (PM) updates outlook on account of certain factors including the impacts from various product and marketing efforts.
Philip Morris (PM) Q2 Earnings: Will RRPs Steal the Show?
by Zacks Equity Research
Philip Morris' (PM) second-quarter 2018 results are likely to gain from rising RRPs demand. However, cigarette volumes will remain soft.
Can Smucker's Shareholder-Friendly Moves Help Revive Stock?
by Zacks Equity Research
Smucker (SJM) announces a quarterly dividend hike of 9% from 78 cents per share to 85 cents. This marks the company's 17th straight year of dividend hike.
Meet Juul, the $15 Billion E-Cig Startup with an Identity Crisis
by Nimah Quadri
In a recent fundraising round, e-cigarette maker Juul Labs Inc. raised $650 million, which values the rapidly-growing, yet still-controversial startup around $15 billion.
Philip Morris (PM) Focused on RRPS, Inks Deal with Parallax
by Zacks Equity Research
Phillip Morris (PM) joins hands with Parallax to develop and expand reduced-risk products in order to counter strict government regulations and changing consumer trends due to health hazards.
Can RRPS, Pricing Aid Revival at Phillip Morris (PM) Stock?
by Zacks Equity Research
Regulatory hurdles and rising health consciousness have been hurting Phillip Morris (PM) cigarette volumes. However, strength in RRPs and solid pricing efforts bode well.
Company News For Jun 11, 2018
by Zacks Equity Research
Companies In The News are: SFIX,DOCU,GE,PM
Philip Morris (PM) Down 5.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Philip Morris (PM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Altria (MO) Stock Recover on RRPs and Shareholder Moves?
by Zacks Equity Research
Altria (MO) consistently focuses on strengthening RRPs category to offset declining cigarette volumes. Its shareholder friendly moves bode well.
Top Analyst Reports for Philip Morris, ConocoPhillips & Alibaba
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Philip Morris (PM), ConocoPhillips (COP) and Alibaba (BABA).
All Rosy for Consumer Staples Stocks? Not Really
by Zacks Equity Research
The consumer staples space is grappling with rising input costs as well as intense competition, with the latter stemming from consumers' changing preferences.
Innovation, Buyouts & More to Fuel Consumer Staples Growth
by Zacks Equity Research
With growth hard to come by for companies in this mature space, Consumer Staples players have to remain focused on squeezing more out of their operations.
Is Phillip Morris' Weak Volumes a Concern for Tobacco Firms?
by vidya Nair
Weak shipment volumes stemming from declining cigarette sales have long been a hurdle for firms in the tobacco space. However, RRPs are likely to continue expanding.
Zacks Investment Ideas feature highlights: Phillip Morris International, Altria and British American Tobacco
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Phillip Morris International, Altria and British American Tobacco
Can Smokeless Unit Aid Altria (MO) This Earnings Season?
by Zacks Equity Research
Altria's (MO) first-quarter 2018 results are likely to benefit from RRPs. However, dismal cigarette volumes are a concern.
Philip Morris (PM) Tops Q1 Earnings, Ups '18 Earnings View
by Zacks Equity Research
Philip Morris's (PM) Q1 earnings came ahead of the Zacks Consensus Estimate while revenues missed the same.
Are Cigarettes Finally Dead? Phillip Morris Plunges
by David Borun
Despite beating estimates for net Q1 earnings, the international tobacco giant plunges, taking industry peers with
Philip Morris (PM) Q1 Earnings: Can RRPs Pare Cigarette Woe?
by Zacks Equity Research
Although Philip Morris (PM) continues to struggle with lower cigarette consumption, its first-quarter 2018 results are likely to gain from steady advancements in reduced risk products.
How MO & 3 Others Are Placed in a Challenging Tobacco Space
by vidya Nair
While stringent FDA regulations mar cigarette sales, tobacco firms are trying to stay afloat with RRPs.
What Philip Morris' Plant Conversion Could Mean for the Stock
by Zacks Equity Research
Philip Morris (PM) continues to enhance its RRPs category. The company announces plans to convert one of its cigarette production facilities in Greece for manufacturing smoke-free tobacco units.
Altria Loses 15% in a Year: Can Strategic Efforts Aid Growth?
by Zacks Equity Research
Amid numerous headwinds plaguing cigarette consumption, Altria (MO) manages to stay afloat in the industry on the back of smokeless products and strong pricing strategies.